Alessandro Morabito

33PUBLICATIONS
101CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersTumour immunologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jul 27, 2026
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.

|Jun 25, 2026
MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells.

|Mar 03, 2026
An ISO 31000-Based Risk Matrix for Risk Management in Anticancer Drug Prescription, Compounding, and Administration for Lung Cancer Patients Treated in a Day Hospital Setting.

Alessandro Morabito, Piera Maiolino, Stefania D'Auria

|Feb 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Antonello Veccia, Ettore D'Argento, Floriana Morgillo

|Feb 25, 2025
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting.

Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili

|Feb 04, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio

Pageof 6

Frequent Collaborators

14 joint publications

Nicola Normanno

5 joint publications

Giacomo Pascarella

4 joint publications

Vincenzo Sforza

4 joint publications

Monica Rosaria Maiello